{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for prednisolone root_names_stdName in Standardized Name (approximate match)
Class (Stereo):
CHEMICAL (RACEMIC)
Nisbuterol, a nicotinic acid ester, is a bronchodilator.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Oxabrexine was developed as a diuretic; however, this compound has never been marketed. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Clentiazem is a chloride derivative of diltiazem, originated in Tanabe Seiyaku. It works as a blocker of calcium channels. The drug was investigated in the clinical trials for the treatment of stable angina, and essential hypertension. Despite the positive results of clinical trials, no development of the drug was reported.
Status:
Investigational
Source:
INN:pyrrolifene [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Pyrroliphene is a dialkylaminodiphenylbutanol ester with antitussive and analgesic activities. In clinical trials the major side effect of Pyrroliphene was sedation, and the other side effect liabilities were similar to those of morphine.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cicortonide is a synthetic cyano-glucocorticoid with anti-inflammatory and antirheumatic, as well as antiallergenic properties.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mespirenone (ZK 94679, 15β,16β-methylene-spironolactone) is a steroid aldosterone antagonist. In addition, it is a quite specific inhibitor of adrenocortical mineralocorticoid synthesis. In rodents mespirenone effectively prevents aldosterone-induced hypertension. It exerts natriuretic efficacy. Although it reached phase II clinical trials, it was discontinued in 1989.
Status:
Investigational
Source:
INN:diacetamate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Diacetamate (Acetaminophen Acetate, Acetaminophen Impurity, diacetyl-p-aminophenol) is a acetaminophen synthetic impurity. Acetaminophen-aspirin
mixtures have lower stability due to acetylation of the former
by the latter, producing diacetyl-p-aminophenol.
Status:
Investigational
Source:
NCT00389792: Phase 2 Interventional Completed Atrial Fibrillation
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Budiodarone is a chemical analog of amiodarone with mixed ion channel electrophysiological activity. Budiodarone was developed to capitalize on the proven efficacy of amiodarone and to avoid its side effects. Budiodarone has a short plasma half-life (7 h) and a lower volume of distribution (13 L/kg). It is cleared from the body in 48 h. Like amiodarone, Budiodarone has balanced, multiple cardiac ion channel inhibiting activity, giving it properties of all four Vaughan Williams antiarrhythmic drug classes. Budiodarone, unlike amiodarone, undergoes rapid metabolism by plasma and tissue esterases. In clinical trials, Budiodarone effectively reduces the number and duration of atrial tachycardia/atrial fibrillation episodes.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Rifametane (SPA-S-565) is a semisynthetic derivative of rifamycin (a natural antibiotic produced by Amycolatopsis rifamycinica). It was being evaluated for treatment of bacterial infections. A phase I study showed that administration of rifametane is safe with minor, reversible adverse events such as mild headache, metallic taste and slightly elevated temperature for 3 to 4 hours. Rifametane has anti-tuberculosis activity and was suggested to be a good candidate for phase II clinical trials.